https://www.cancernetwork.com/view/futibatinib-yields-clinical-benefit-in-fgfr2-intrahepatic-cholangiocarcinoma
0
0
2/5/23 at 5:05pm
Organization
Cancernetwork.com
Author
Russ Conroy
31 words
0
Comments
According to findings from a phase 2 clinical study, futibatinib may achieve benefit in patients with intrahepatic cholangiocarcinoma harboring FGFR2¬ rearrangements.
You are the first to view
Create an account
or login to join the discussion